Underlying mechanisms mediating the antidepressant effects of estrogens

Biochimica et Biophysica Acta - General Subjects

Volumn 1800, Issue 10, 2010, Pages 1136-1144

  Österlund, Marie K ^a  

^a Karo Bio   (Sweden)

Author keywords

Affective disorders; Depression; Estradiol; Estrogen; Serotonin

Indexed keywords

1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; COUMESTROL; DESIPRAMINE; DIARYLPROPIONITRILE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA AGONIST; FENCLONINE; FLUOXETINE; FULVESTRANT; GESTAGEN; HORMONE RECEPTOR STIMULATING AGENT; NEUROTRANSMITTER; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; POSTSYNAPTIC RECEPTOR; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAY 200070;

ANXIETY DISORDER; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DENTATE GYRUS; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; ESTROGEN ACTIVITY; ESTROGEN THERAPY; HIGH RISK PATIENT; HIPPOCAMPUS; HORMONAL REGULATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KNOCKOUT MOUSE; LOW DRUG DOSE; MAJOR DEPRESSION; MOOD DISORDER; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROTROPISM; NONHUMAN; NORADRENERGIC SYSTEM; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAPHE NUCLEUS; REGULATORY MECHANISM; REVIEW; SEROTONIN RELEASE; SEROTONINERGIC NERVE CELL; SEROTONINERGIC TRANSMISSION; SINGLE DRUG DOSE; AGONISTS; ANIMAL; DRUG EFFECTS; METABOLISM; MOUSE; NERVE CELL; RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; DEPRESSION; ESTROGEN RECEPTOR BETA; ESTROGENS; HUMANS; MICE; NEURONAL PLASTICITY; NEURONS; RAPHE NUCLEI; RATS; RECEPTORS, SEROTONIN; SEROTONIN;

RODENTIA;

EID: 77956179858     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2009.11.001     Document Type: Review

References (156)

1. Kessler R.C., McGonagle K.A., Zhao S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry 1994, 51:8-19.
2. Weissman M.M., Bland R., Joyce P.R., Newman S., Wells J.E., Wittchen H.U. Sex differences in rates of depression: cross-national perspectives. J. Affect. Disord. 1993, 29:77-84.
3. Halbreich U., Kahn L.S. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 2001, 15:797-817.
4. Freeman E.W., Sammel M.D., Lin H., Nelson D.B. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch. Gen. Psychiatry 2006, 63:375-382.
5. Schmidt P.J., Murphy J.H., Haq N., Danaceau M.A., St Clair L. Basal plasma hormone levels in depressed perimenopausal women. Psychoneuroendocrinology 2002, 27:907-920.
6. Rubinow D.R., Schmidt P.J., Roca C.A. Hormone measures in reproductive endocrine-related mood disorders: diagnostic issues. Psychopharmacol. Bull. 1998, 34:289-290.
7. Payne J.L. The role of estrogen in mood disorders in women. Int. Rev. Psychiatry 2003, 15:280-290.
8. Epperson C.N., Wisner K.L., Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom. Med. 1999, 61:676-697.
9. Grigoriadis S., Kennedy S.H. Role of estrogen in the treatment of depression. Am. J. Ther. 2002, 9:503-509.
10. Rasgon N.L., Altshuler L.L., Fairbanks L.A., et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J. Clin. Psychiatry 2002, 63(Suppl. 7):45-48.
11. Schmidt P.J., Nieman L., Danaceau M.A., et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am. J. Obstet. Gynecol. 2000, 183:414-420.
12. Soares C.N., Almeida O.P., Joffe H., Cohen L.S. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2001, 58:529-534.
13. Cohen L.S., Soares C.N., Poitras J.R., Prouty J., Alexander A.B., Shifren J.L. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. Am. J. Psychiatry 2003, 160:1519-1522.
14. Pae C.U., Mandelli L., Kim T.S., et al. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. Biomed. Pharmacother. 2009, 63:228-235.
15. Pinto-Meza A., Usall J., Serrano-Blanco A., Suarez D., Haro J.M. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference?. J. Affect. Disord. 2006, 93:53-60.
16. Thase M.E., Entsuah R., Cantillon M., Kornstein S.G. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J. Womens Health (Larchmt) 2005, 14:609-616.
17. Amsterdam J., Garcia-Espana F., Fawcett J., et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J. Affect. Disord. 1999, 55:11-17.
18. Morgan M.L., Cook I.A., Rapkin A.J., Leuchter A.F. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J. Clin. Psychiatry 2005, 66:774-780.
19. Schneider L.S., Small G.W., Hamilton S.H., Bystritsky A., Nemeroff C.B., Meyers B.S. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Am. J. Geriatr. Psychiatry 1997, 5:97-106.
20. Zanardi R., Rossini D., Magri L., Malaguti A., Colombo C., Smeraldi E. Response to SSRIs and role of the hormonal therapy in post-menopausal depression. Eur. Neuropsychopharmacol. 2007, 17:400-405.
21. Kuiper G.G., Carlsson B., Grandien K., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138:863-870.
22. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
23. Laflamme N., Nappi R.E., Drolet G., Labrie C., Rivest S. Expression and neuropeptidergic characterization of estrogen receptors (ERalpha and ERbeta) throughout the rat brain: anatomical evidence of distinct roles of each subtype. J. Neurobiol. 1998, 36:357-378.
24. Merchenthaler I., Lane M.V., Numan S., Dellovade T.L. Distribution of estrogen receptor alpha and beta in the mouse central nervous system: in vivo autoradiographic and immunocytochemical analyses. J. Comp. Neurol. 2004, 473:270-291.
25. Osterlund M.K., Gustafsson J.A., Keller E., Hurd Y.L. Estrogen receptor beta (ERbeta) messenger ribonucleic acid (mRNA) expression within the human forebrain: distinct distribution pattern to ERalpha mRNA. J. Clin. Endocrinol. Metab. 2000, 85:3840-3846.
26. Mitra S.W., Hoskin E., Yudkovitz J., et al. Immunolocalization of estrogen receptor beta in the mouse brain: comparison with estrogen receptor alpha. Endocrinology 2003, 144:2055-2067.
27. Osterlund M.K., Hurd Y.L. Estrogen receptors in the human forebrain and the relation to neuropsychiatric disorders. Prog. Neurobiol. 2001, 64:251-267.
28. Gundlah C., Lu N.Z., Mirkes S.J., Bethea C.L. Estrogen receptor beta (ERbeta) mRNA and protein in serotonin neurons of macaques. Brain Res. Mol. Brain Res. 2001, 91:14-22.
29. Gundlah C., Alves S.E., Clark J.A., Pai L.Y., Schaeffer J.M., Rohrer S.P. Estrogen receptor-beta regulates tryptophan hydroxylase-1 expression in the murine midbrain raphe. Biol. Psychiatry 2005, 57:938-942.
30. Sanchez R.L., Reddy A.P., Centeno M.L., Henderson J.A., Bethea C.L. A second tryptophan hydroxylase isoform, TPH-2 mRNA, is increased by ovarian steroids in the raphe region of macaques. Brain Res. Mol. Brain Res. 2005, 135:194-203.
31. Hiroi R., McDevitt R.A., Neumaier J.F. Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field. Biol. Psychiatry 2006, 60:288-295.
32. Bethea C.L., Mirkes S.J., Shively C.A., Adams M.R. Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biol. Psychiatry 2000, 47:562-576.
33. Donner N.C., Handa R.J. Estrogen receptor beta regulates the expression of tryptophan-hydroxylase 2 mRNA within serotonergic neurons of the rat dorsal raphe nuclei. Neuroscience 2009, 163:705-718.
34. Bethea C.L., Lu N.Z., Gundlah C., Streicher J.M. Diverse actions of ovarian steroids in the serotonin neural system. Front. Neuroendocrinol. 2002, 23:41-100.
35. Gundlah C., Lu N.Z., Bethea C.L. Ovarian steroid regulation of monoamine oxidase-A and -B mRNAs in the macaque dorsal raphe and hypothalamic nuclei. Psychopharmacology (Berl) 2002, 160:271-282.
36. Ortega-Corona B.G., Valencia-Sanchez A., Kubli-Garfias C., et al. Hypothalamic monoamine oxidase activity in ovariectomized rats after sexual behavior restoration. Arch. Med. Res. 1994, 25:337-340.
37. Luine V.N., Rhodes J.C. Gonadal hormone regulation of MAO and other enzymes in hypothalamic areas. Neuroendocrinology 1983, 36:235-241.
38. Sanchez C., Bergqvist P.B., Brennum L.T., et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003, 167:353-362.
39. Blier P., de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 1999, 21:91S-98S.
40. Robichaud M., Debonnel G. Oestrogen and testosterone modulate the firing activity of dorsal raphe nucleus serotonergic neurones in both male and female rats. J. Neuroendocrinol. 2005, 17:179-185.
41. El Mansari M., Sanchez C., Chouvet G., Renaud B., Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 2005, 30:1269-1277.
42. Hughes Z.A., Liu F., Platt B.J., et al. WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent. Neuropharmacology 2008, 54:1136-1142.
43. Lu N.Z., Bethea C.L. Ovarian steroid regulation of 5-HT1A receptor binding and G protein activation in female monkeys. Neuropsychopharmacology 2002, 27:12-24.
44. Pecins-Thompson M., Bethea C.L. Ovarian steroid regulation of serotonin-1A autoreceptor messenger RNA expression in the dorsal raphe of rhesus macaques. Neuroscience 1999, 89:267-277.
45. Birzniece V., Johansson I.M., Wang M.D., Seckl J.R., Backstrom T., Olsson T. Serotonin 5-HT(1A) receptor mRNA expression in dorsal hippocampus and raphe nuclei after gonadal hormone manipulation in female rats. Neuroendocrinology 2001, 74:135-142.
46. Hiroi R., Neumaier J.F. Estrogen decreases 5-HT1B autoreceptor mRNA in selective subregion of rat dorsal raphe nucleus: inverse association between gene expression and anxiety behavior in the open field. Neuroscience 2009, 158:456-464.
47. Neuropsychopharmacology: The Fifth Generation of Progress 2002, Lippinkott Williams & Wilkins, Nashville. 5th ed. K.L. Davis, D. Charney, J.T. Coyle, C.B. Nemeroff (Eds.).
48. Amargos-Bosch M., Bortolozzi A., Puig M.V., et al. Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. Cereb. Cortex 2004, 14:281-299.
49. Celada P., Puig M., Amargos-Bosch M., Adell A., Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J. Psychiatry Neurosci. 2004, 29:252-265.
50. Celada P., Puig M.V., Casanovas J.M., Guillazo G., Artigas F. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: Involvement of serotonin-1A, GABA(A), and glutamate receptors. J. Neurosci. 2001, 21:9917-9929.
51. Martin-Ruiz R., Puig M.V., Celada P., et al. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J. Neurosci. 2001, 21:9856-9866.
52. Puig M.V., Celada P., Diaz-Mataix L., Artigas F. In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents. Cereb. Cortex 2003, 13:870-882.
53. Drevets W.C. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr. Opin. Neurobiol. 2001, 11:240-249.
54. Baxter L.R., Schwartz J.M., Phelps M.E., et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch. Gen. Psychiatry 1989, 46:243-250.
55. Hrdina P.D., Vu T.B. Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain: an autoradiographic study. Synapse 1993, 14:324-331.
56. Kugaya A., Epperson C.N., Zoghbi S., et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am. J. Psychiatry 2003, 160:1522-1524.
57. Cyr M., Bosse R., Di Paolo T. Gonadal hormones modulate 5-hydroxytryptamine2A receptors: emphasis on the rat frontal cortex. Neuroscience 1998, 83:829-836.
58. Sumner B.E., Fink G. Testosterone as well as estrogen increases serotonin2A receptor mRNA and binding site densities in the male rat brain. Brain Res. Mol. Brain Res. 1998, 59:205-214.
59. Sumner B.E., Grant K.E., Rosie R., Hegele-Hartung C., Fritzemeier K.H., Fink G. Effects of tamoxifen on serotonin transporter and 5-hydroxytryptamine(2A) receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement. Brain Res. Mol. Brain Res. 1999, 73:119-128.
60. Mize A.L., Alper R.H. Acute and long-term effects of 17beta-estradiol on G(i/o) coupled neurotransmitter receptor function in the female rat brain as assessed by agonist-stimulated [35S]GTPgammaS binding. Brain Res. 2000, 859:326-333.
61. Mize A.L., Poisner A.M., Alper R.H. Estrogens act in rat hippocampus and frontal cortex to produce rapid, receptor-mediated decreases in serotonin 5-HT(1A) receptor function. Neuroendocrinology 2001, 73:166-174.
62. Osterlund M.K., Halldin C., Hurd Y.L. Effects of chronic 17beta-estradiol treatment on the serotonin 5-HT(1A) receptor mRNA and binding levels in the rat brain. Synapse 2000, 35:39-44.
63. Osterlund M.K., Hurd Y.L. Acute 17 beta-estradiol treatment down-regulates serotonin 5HT1A receptor mRNA expression in the limbic system of female rats. Brain Res. Mol. Brain Res. 1998, 55:169-172.
64. Osterlund M.K., Overstreet D.H., Hurd Y.L. The Flinders sensitive line rats, a genetic model of depression, show abnormal serotonin receptor mRNA expression in the brain that is reversed by 17beta-estradiol. Brain Res. Mol. Brain Res. 1999, 74:158-166.
65. Etgen A.M., Karkanias G.B. Estrogen regulation of noradrenergic signaling in the hypothalamus. Psychoneuroendocrinology 1994, 19:603-610.
66. Ostlund H., Keller E., Hurd Y.L. Estrogen receptor gene expression in relation to neuropsychiatric disorders. Ann. N.Y. Acad. Sci. 2003, 1007:54-63.
67. Serova L., Rivkin M., Nakashima A., Sabban E.L. Estradiol stimulates gene expression of norepinephrine biosynthetic enzymes in rat locus coeruleus. Neuroendocrinology 2002, 75:193-200.
68. Chen Z., Skolnick P. Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert. Opin. Investig. Drugs 2007, 16:1365-1377.
69. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 2007, 64:327-337.
70. Creutz L.M., Kritzer M.F. Estrogen receptor-beta immunoreactivity in the midbrain of adult rats: regional, subregional, and cellular localization in the A10, A9, and A8 dopamine cell groups. J. Comp. Neurol. 2002, 446:288-300.
71. Liu B., Xie J. Increased dopamine release in vivo by estradiol benzoate from the central amygdaloid nucleus of Parkinson's disease model rats. J. Neurochem. 2004, 90:654-658.
72. Le Saux M., Di Paolo T. Influence of oestrogenic compounds on monoamine transporters in rat striatum. J. Neuroendocrinol. 2006, 18:25-32.
73. Le Saux M., Morissette M., Di Paolo T. ERbeta mediates the estradiol increase of D2 receptors in rat striatum and nucleus accumbens. Neuropharmacology 2006, 50:451-457.
74. Pasqualini C., Olivier V., Guibert B., Frain O., Leviel V. Acute stimulatory effect of estradiol on striatal dopamine synthesis. J. Neurochem. 1995, 65:1651-1657.
75. Sheline Y.I. Neuroimaging studies of mood disorder effects on the brain. Biol. Psychiatry 2003, 54:338-352.
76. Sheline Y.I., Gado M.H., Kraemer H.C. Untreated depression and hippocampal volume loss. Am. J. Psychiatry 2003, 160:1516-1518.
77. Cook S.C., Wellman C.L. Chronic stress alters dendritic morphology in rat medial prefrontal cortex. J. Neurobiol. 2004, 60:236-248.
78. Czeh B., Muller-Keuker J.I., Rygula R., et al. Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology 2007, 32:1490-1503.
79. Banasr M., Valentine G.W., Li X.Y., Gourley S.L., Taylor J.R., Duman R.S. Chronic unpredictable stress decreases cell proliferation in the cerebral cortex of the adult rat. Biol. Psychiatry 2007, 62:496-504.
80. Malberg J.E., Schechter L.E. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr. Pharm. Des. 2005, 11:145-155.
81. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 2000, 20:9104-9110.
82. Duman R.S., Nakagawa S., Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 2001, 25:836-844.
83. Sairanen M., O'Leary O.F., Knuuttila J.E., Castren E. Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medial prefrontal cortex of the rat. Neuroscience 2007, 144:368-374.
84. Kalita K., Szymczak S., Kaczmarek L. Non-nuclear estrogen receptor beta and alpha in the hippocampus of male and female rats. Hippocampus 2005, 15:404-412.
85. Milner T.A., Ayoola K., Drake C.T., et al. Ultrastructural localization of estrogen receptor beta immunoreactivity in the rat hippocampal formation. J. Comp. Neurol. 2005, 491:81-95.
86. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 2002, 22:3251-3261.
87. Siuciak J.A., Lewis D.R., Wiegand S.J., Lindsay R.M. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav. 1997, 56:131-137.
88. Mamounas L.A., Blue M.E., Siuciak J.A., Altar C.A. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J. Neurosci. 1995, 15:7929-7939.
89. Gibbs R.B. Levels of trkA and BDNF mRNA, but not NGF mRNA, fluctuate across the estrous cycle and increase in response to acute hormone replacement. Brain Res. 1998, 787:259-268.
90. Singh M., Meyer E.M., Simpkins J.W. The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. Endocrinology 1995, 136:2320-2324.
91. Sohrabji F., Miranda R.C., Toran-Allerand C.D. Identification of a putative estrogen response element in the gene encoding brain-derived neurotrophic factor. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:11110-11114.
92. Berchtold N.C., Kesslak J.P., Pike C.J., Adlard P.A., Cotman C.W. Estrogen and exercise interact to regulate brain-derived neurotrophic factor mRNA and protein expression in the hippocampus. Eur. J. Neurosci. 2001, 14:1992-2002.
93. Blurton-Jones M., Kuan P.N., Tuszynski M.H. Anatomical evidence for transsynaptic influences of estrogen on brain-derived neurotrophic factor expression. J. Comp. Neurol. 2004, 468:347-360.
94. Blurton-Jones M., Tuszynski M.H. Estradiol-induced modulation of estrogen receptor-beta and GABA within the adult neocortex: a potential transsynaptic mechanism for estrogen modulation of BDNF. J. Comp. Neurol. 2006, 499:603-612.
95. Santarelli L., Saxe M., Gross C., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
96. Mazzucco C.A., Lieblich S.E., Bingham B.I., Williamson M.A., Viau V., Galea L.A. Both estrogen receptor alpha and estrogen receptor beta agonists enhance cell proliferation in the dentate gyrus of adult female rats. Neuroscience 2006, 141:1793-1800.
97. Barha C.K., Lieblich S.E., Galea L.A. Different forms of oestrogen rapidly upregulate cell proliferation in the dentate gyrus of adult female rats. J. Neuroendocrinol. 2009, 21:155-166.
98. Tanapat P., Hastings N.B., Reeves A.J., Gould E. Estrogen stimulates a transient increase in the number of new neurons in the dentate gyrus of the adult female rat. J. Neurosci. 1999, 19:5792-5801.
99. Wang J.M., Liu L., Brinton R.D. Estradiol-17beta-induced human neural progenitor cell proliferation is mediated by an estrogen receptor beta-phosphorylated extracellularly regulated kinase pathway. Endocrinology 2008, 149:208-218.
100. Herrick S.P., Waters E.M., Drake C.T., McEwen B.S., Milner T.A. Extranuclear estrogen receptor beta immunoreactivity is on doublecortin-containing cells in the adult and neonatal rat dentate gyrus. Brain Res. 2006, 1121:46-58.
101. Saravia F., Beauquis J., Pietranera L., De Nicola A.F. Neuroprotective effects of estradiol in hippocampal neurons and glia of middle age mice. Psychoneuroendocrinology 2007, 32:480-492.
102. Banasr M., Hery M., Brezun J.M., Daszuta A. Serotonin mediates oestrogen stimulation of cell proliferation in the adult dentate gyrus. Eur. J. Neurosci. 2001, 14:1417-1424.
103. Aberg M.A., Aberg N.D., Hedbacker H., Oscarsson J., Eriksson P.S. Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus. J. Neurosci. 2000, 20:2896-2903.
104. Hoshaw B.A., Malberg J.E., Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 2005, 1037:204-208.
105. El-Bakri N.K., Islam A., Suliman I., Lindgren U., Winblad B., Adem A. Ovariectomy and gonadal hormone treatment: effects on insulin-like growth factor-1 receptors in the rat brain. Growth Horm. IGF Res. 2004, 14:388-393.
106. Perez-Martin M., Azcoitia I., Trejo J.L., Sierra A., Garcia-Segura L.M. An antagonist of estrogen receptors blocks the induction of adult neurogenesis by insulin-like growth factor-I in the dentate gyrus of adult female rat. Eur. J. Neurosci. 2003, 18:923-930.
107. Sairanen M., Lucas G., Ernfors P., Castren M., Castren E. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J. Neurosci. 2005, 25:1089-1094.
108. Li Y., Luikart B.W., Birnbaum S., et al. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 2008, 59:399-412.
109. Liu F., Day M., Muniz L.C., et al. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat. Neurosci. 2008, 11:334-343.
110. Mhyre A.J., Dorsa D.M. Estrogen activates rapid signaling in the brain: role of estrogen receptor alpha and estrogen receptor beta in neurons and glia. Neuroscience 2006, 138:851-858.
111. Rajkowska G., Miguel-Hidalgo J.J. Gliogenesis and glial pathology in depression. CNS Neurol. Disord. Drug Targets 2007, 6:219-233.
112. Ongur D., Drevets W.C., Price J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13290-13295.
113. Cotter D., Mackay D., Chana G., Beasley C., Landau S., Everall I.P. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb. Cortex 2002, 12:386-394.
114. Cotter D., Mackay D., Landau S., Kerwin R., Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch. Gen. Psychiatry 2001, 58:545-553.
115. Cotter D.R., Pariante C.M., Everall I.P. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res. Bull 2001, 55:585-595.
116. Kodama M., Fujioka T., Duman R.S. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol. Psychiatry 2004, 56:570-580.
117. Lindheim S.R., Legro R.S., Bernstein L., et al. Behavioral stress responses in premenopausal and postmenopausal women and the effects of estrogen. Am. J. Obstet. Gynecol. 1992, 167:1831-1836.
118. Bethea C.L., Centeno M.L. Ovarian steroid treatment decreases corticotropin-releasing hormone (CRH) mRNA and protein in the hypothalamic paraventricular nucleus of ovariectomized monkeys. Neuropsychopharmacology 2008, 33:546-556.
119. Li X.F., Mitchell J.C., Wood S., Coen C.W., Lightman S.L., O'Byrne K.T. The effect of oestradiol and progesterone on hypoglycaemic stress-induced suppression of pulsatile luteinizing hormone release and on corticotropin-releasing hormone mRNA expression in the rat. J. Neuroendocrinol. 2003, 15:468-476.
120. Roy B.N., Reid R.L., Van Vugt D.A. The effects of estrogen and progesterone on corticotropin-releasing hormone and arginine vasopressin messenger ribonucleic acid levels in the paraventricular nucleus and supraoptic nucleus of the rhesus monkey. Endocrinology 1999, 140:2191-2198.
121. Burgess L.H., Handa R.J. Chronic estrogen-induced alterations in adrenocorticotropin and corticosterone secretion, and glucocorticoid receptor-mediated functions in female rats. Endocrinology 1992, 131:1261-1269.
122. Lund T.D., Rovis T., Chung W.C., Handa R.J. Novel actions of estrogen receptor-beta on anxiety-related behaviors. Endocrinology 2005, 146:797-807.
123. Weiser M.J., Handa R.J. Estrogen impairs glucocorticoid dependent negative feedback on the hypothalamic-pituitary-adrenal axis via estrogen receptor alpha within the hypothalamus. Neuroscience 2009, 159:883-895.
124. Handa R.J., Weiser M.J., Zuloaga D.G. A role for the androgen metabolite, 5alpha-androstane-3beta,17beta-diol, in modulating oestrogen receptor beta-mediated regulation of hormonal stress reactivity. J. Neuroendocrinol. 2009, 21:351-358.
125. Patisaul H.B., Scordalakes E.M., Young L.J., Rissman E.F. Oxytocin, but not oxytocin receptor, is regulated by oestrogen receptor beta in the female mouse hypothalamus. J. Neuroendocrinol. 2003, 15:787-793.
126. Shughrue P.J., Dellovade T.L., Merchenthaler I. Estrogen modulates oxytocin gene expression in regions of the rat supraoptic and paraventricular nuclei that contain estrogen receptor-beta. Prog. Brain Res. 2002, 139:15-29.
127. Osterlund M.K., Grandien K., Keller E., Hurd Y.L. The human brain has distinct regional expression patterns of estrogen receptor alpha mRNA isoforms derived from alternative promoters. J. Neurochem. 2000, 75:1390-1397.
128. Blurton-Jones M.M., Roberts J.A., Tuszynski M.H. Estrogen receptor immunoreactivity in the adult primate brain: neuronal distribution and association with p75, trkA, and choline acetyltransferase. J. Comp. Neurol. 1999, 405:529-542.
129. Perez S., Sendera T.J., Kordower J.H., Mufson E.J. Estrogen receptor alpha containing neurons in the monkey forebrain: lack of association with calcium binding proteins and choline acetyltransferase. Brain Res. 2004, 1019:55-63.
130. Walf A.A., Frye C.A. A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology 2006, 31:1097-1111.
131. Marcondes F.K., Miguel K.J., Melo L.L., Spadari-Bratfisch R.C. Estrous cycle influences the response of female rats in the elevated plus-maze test. Physiol. Behav. 2001, 74:435-440.
132. Mora S., Dussaubat N., Diaz-Veliz G. Effects of the estrous cycle and ovarian hormones on behavioral indices of anxiety in female rats. Psychoneuroendocrinology 1996, 21:609-620.
133. Walf A.A., Rhodes M.E., Frye C.A. Antidepressant effects of ERbeta-selective estrogen receptor modulators in the forced swim test. Pharmacol. Biochem. Behav. 2004, 78:523-529.
134. Estrada-Camarena E., Fernandez-Guasti A., Lopez-Rubalcava C. Antidepressant-like effect of different estrogenic compounds in the forced swimming test. Neuropsychopharmacology 2003, 28:830-838.
135. Walf A.A., Frye C.A. ERbeta-selective estrogen receptor modulators produce antianxiety behavior when administered systemically to ovariectomized rats. Neuropsychopharmacology 2005, 30:1598-1609.
136. Rachman I.M., Unnerstall J.R., Pfaff D.W., Cohen R.S. Estrogen alters behavior and forebrain c-fos expression in ovariectomized rats subjected to the forced swim test. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13941-13946.
137. Dalla C., Antoniou K., Papadopoulou-Daifoti Z., Balthazart J., Bakker J. Oestrogen-deficient female aromatase knockout (ArKO) mice exhibit depressive-like symptomatology. Eur. J. Neurosci. 2004, 20:217-228.
138. Estrada-Camarena E., Rivera N.M., Berlanga C., Fernandez-Guasti A. Reduction in the latency of action of antidepressants by 17 beta-estradiol in the forced swimming test. Psychopharmacology (Berl) 2008, 201:351-360.
139. Sell S.L., Craft R.M., Seitz P.K., Stutz S.J., Cunningham K.A., Thomas M.L. Estradiol-sertraline synergy in ovariectomized rats. Psychoneuroendocrinology 2008, 33:1051-1060.
140. Weiser M.J., Wu T.J., Handa R.J. Estrogen receptor-beta agonist diarylpropionitrile: biological activities of R- and S-enantiomers on behavior and hormonal response to stress. Endocrinology 2009, 150:1817-1825.
141. Imwalle D.B., Gustafsson J.A., Rissman E.F. Lack of functional estrogen receptor beta influences anxiety behavior and serotonin content in female mice. Physiol. Behav. 2005, 84:157-163.
142. Krezel W., Dupont S., Krust A., Chambon P., Chapman P.F. Increased anxiety and synaptic plasticity in estrogen receptor beta-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12278-12282.
143. Rocha B.A., Fleischer R., Schaeffer J.M., Rohrer S.P., Hickey G.J. 17beta-Estradiol-induced antidepressant-like effect in the forced swim test is absent in estrogen receptor-beta knockout (BERKO) mice. Psychopharmacology (Berl) 2005, 179:637-643.
144. Walf A.A., Ciriza I., Garcia-Segura L.M., Frye C.A. Antisense oligodeoxynucleotides for estrogen receptor-beta and alpha attenuate estradiol's modulation of affective and sexual behavior, respectively. Neuropsychopharmacology 2008, 33:431-440.
145. Walf A.A., Frye C.A. Administration of estrogen receptor beta-specific selective estrogen receptor modulators to the hippocampus decrease anxiety and depressive behavior of ovariectomized rats. Pharmacol. Biochem. Behav. 2007, 86:407-414.
146. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. Jama 2002, 288:321-333.
147. Bodo C., Rissman E.F. New roles for estrogen receptor beta in behavior and neuroendocrinology. Front. Neuroendocrinol. 2006, 27:217-232.
148. Harris H.A., Albert L.M., Leathurby Y., et al. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 2003, 144:4241-4249.
149. Merchenthaler I., Hoffman G.E., Lane M.V. Estrogen and estrogen receptor-{beta} (ER{beta})-selective ligands induce galanin expression within gonadotropin hormone-releasing hormone-immunoreactive neurons in the female rat brain. Endocrinology 2005, 146:2760-2765.
150. Couse J.F., Yates M.M., Walker V.R., Korach K.S. Characterization of the hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) null mice reveals hypergonadism and endocrine sex reversal in females lacking ERalpha but not ERbeta. Mol. Endocrinol. 2003, 17:1039-1053.
151. Frasor J., Barnett D.H., Danes J.M., Hess R., Parlow A.F., Katzenellenbogen B.S. Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus. Endocrinology 2003, 144:3159-3166.
152. Harris H.A., Katzenellenbogen J.A., Katzenellenbogen B.S. Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology 2002, 143:4172-4177.
153. Crabtree J.S., Zhang X., Peano B.J., Zhang Z., Winneker R.C., Harris H.A. Development of a mouse model of mammary gland versus uterus tissue selectivity using estrogen- and progesterone-regulated gene markers. J. Steroid. Biochem. Mol. Biol. 2006, 101:11-21.
154. Hartman J., Strom A., Gustafsson J.A. Estrogen receptor beta in breast cancer-diagnostic and therapeutic implications. Steroids 2009, 74:635-641.
155. Harris H.A. Estrogen receptor-beta: recent lessons from in vivo studies. Mol. Endocrinol. 2007, 21:1-13.
156. Nemeroff C.B. Prevalence and management of treatment-resistant depression. J. Clin. Psychiatry 2007, 68(Suppl 8):17-25.